# Abbott Laboratories (ABT)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $155.87B  
**Price:** $89.17 (-2.28%)

> Abbott Laboratories is a diversified healthcare company that discovers, develops, manufactures, and sells a comprehensive range of medical products and pharmaceuticals globally. The company operates through four primary segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its medical device portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, and catheters designed to treat cardiovascular and neurological conditions. Abbott also produces continuous glucose monitors for diabetes management and diagnostic equipment including immunoassays and point-of-care testing kits. In nutrition, the company manufactures infant formula, adult nutritional liquids, and specialized dietary products for pediatric and adult populations. Abbott's established pharmaceutical segment offers branded generic medications across multiple therapeutic areas. With headquarters in Abbott Park, Illinois, and operations spanning more than 160 countries, Abbott derives approximately 60 percent of its sales from international markets, making it a truly global healthcare provider serving healthcare professionals, patients, and consumers worldwide.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $44.33B | $25.01B | $8.05B | $6.52B | $3.72 |
| 2024 | $41.95B | $23.24B | $6.83B | $13.40B | $7.64 |
| 2023 | $40.11B | $22.13B | $6.48B | $5.72B | $3.26 |
| 2022 | $43.65B | $24.51B | $8.36B | $6.93B | $3.91 |
| 2021 | $43.08B | $24.54B | $8.43B | $7.07B | $3.94 |
| 2020 | $34.61B | $19.61B | $5.36B | $4.50B | $2.50 |
| 2019 | $31.90B | $18.67B | $4.53B | $3.69B | $2.06 |
| 2018 | $30.58B | $17.87B | $3.65B | $2.37B | $1.33 |
| 2017 | $27.39B | $14.98B | $1.56B | $477M | $0.27 |
| 2016 | $20.85B | $11.76B | $3.03B | $1.40B | $0.94 |
| 2015 | $20.41B | $11.66B | $2.87B | $4.42B | $2.92 |
| 2014 | $20.25B | $11.03B | $2.60B | $2.28B | $1.49 |
| 2013 | $19.66B | $10.46B | $2.13B | $2.58B | $1.62 |
| 2012 | $19.05B | $10.15B | $1.36B | $5.96B | $3.72 |
| 2011 | $21.41B | $11.39B | $1.63B | $4.73B | $3.01 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $86.71B | $34.58B | $52.13B | $8.52B | $12.93B |
| 2024 | $81.41B | $33.75B | $47.66B | $7.62B | $14.13B |
| 2023 | $73.21B | $34.61B | $38.60B | $6.90B | $14.68B |
| 2022 | $74.44B | $37.75B | $36.69B | $9.88B | $16.77B |
| 2021 | $75.20B | $39.39B | $35.80B | $9.80B | $18.05B |
| 2020 | $72.55B | $39.76B | $32.78B | $6.84B | $18.53B |
| 2019 | $67.89B | $36.80B | $31.09B | $3.86B | $17.94B |
| 2018 | $67.17B | $36.65B | $30.52B | $3.84B | $19.37B |
| 2017 | $76.25B | $45.35B | $30.90B | $9.41B | $27.72B |
| 2016 | $52.67B | $32.13B | $20.54B | $18.62B | $20.68B |
| 2015 | $41.25B | $20.04B | $21.21B | $5.00B | $5.87B |
| 2014 | $41.21B | $19.68B | $21.53B | $4.06B | $3.45B |
| 2013 | $42.94B | $17.77B | $25.17B | $3.48B | $3.40B |
| 2012 | $67.23B | $40.51B | $26.72B | $10.80B | $18.39B |
| 2011 | $60.28B | $35.84B | $24.44B | $6.81B | $13.07B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $9.57B | $2.17B | $7.39B |
| 2024 | $8.56B | $2.21B | $6.35B |
| 2023 | $7.26B | $2.20B | $5.06B |
| 2022 | $9.58B | $1.78B | $7.80B |
| 2021 | $10.53B | $1.89B | $8.65B |
| 2020 | $7.90B | $2.18B | $5.72B |
| 2019 | $6.14B | $1.64B | $4.50B |
| 2018 | $6.30B | $1.39B | $4.91B |
| 2017 | $5.57B | $1.14B | $4.43B |
| 2016 | $3.20B | $1.12B | $2.08B |
| 2015 | $2.97B | $1.11B | $1.86B |
| 2014 | $3.67B | $1.08B | $2.60B |
| 2013 | $3.32B | $1.15B | $2.18B |
| 2012 | $9.31B | $1.79B | $7.52B |
| 2011 | $8.97B | $1.49B | $7.48B |

Source: [CompaniesByCap](https://companiesbycap.com/company/ABT)